{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "35544190",
  "DateCompleted": {
    "Year": "2022",
    "Month": "07",
    "Day": "08"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "05",
    "Day": "13"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1001/jamapsychiatry.2022.1074"
    ],
    "Journal": {
      "ISSN": "2168-6238",
      "JournalIssue": {
        "Volume": "79",
        "Issue": "7",
        "PubDate": {
          "Year": "2022",
          "Month": "Jul",
          "Day": "01"
        }
      },
      "Title": "JAMA psychiatry",
      "ISOAbbreviation": "JAMA Psychiatry"
    },
    "ArticleTitle": "Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting.",
    "Pagination": {
      "StartPage": "736",
      "EndPage": "738",
      "MedlinePgn": "736-738"
    },
    "Abstract": {
      "AbstractText": [
        "This comparative analysis examines the trajectory of depression severity among patients treated with intravenous ketamine or intranasal esketamine in a clinical setting."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut."
          }
        ],
        "LastName": "Nikayin",
        "ForeName": "Sina",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut."
          }
        ],
        "LastName": "Rhee",
        "ForeName": "Taeho Greg",
        "Initials": "TG"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Yale University, New Haven, Connecticut."
          }
        ],
        "LastName": "Cunningham",
        "ForeName": "Maria Elena",
        "Initials": "ME"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Yale University School of Medicine, New Haven, Connecticut."
          }
        ],
        "LastName": "de Fontnouvelle",
        "ForeName": "Christina A",
        "Initials": "CA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut."
          }
        ],
        "LastName": "Ostroff",
        "ForeName": "Robert B",
        "Initials": "RB"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut."
          }
        ],
        "LastName": "Sanacora",
        "ForeName": "Gerard",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut."
          }
        ],
        "LastName": "Wilkinson",
        "ForeName": "Samuel T",
        "Initials": "ST"
      }
    ],
    "GrantList": [
      {
        "GrantID": "UL1 TR001863",
        "Acronym": "TR",
        "Agency": "NCATS NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Comment"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "JAMA Psychiatry",
    "NlmUniqueID": "101589550",
    "ISSNLinking": "2168-622X"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antidepressive Agents"
    },
    {
      "RegistryNumber": "50LFG02TXD",
      "NameOfSubstance": "Esketamine"
    },
    {
      "RegistryNumber": "690G0D6V8H",
      "NameOfSubstance": "Ketamine"
    }
  ],
  "CommentsCorrectionsList": [
    {
      "RefSource": "J Affect Disord. 2020 Mar 1;264:527-534",
      "PMID": "31786030"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antidepressive Agents"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy"
      ],
      "DescriptorName": "Depression"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy"
      ],
      "DescriptorName": "Depressive Disorder, Treatment-Resistant"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Ketamine"
    }
  ],
  "CoiStatement": "<b>Conflict of Interest Disclosures:</b> Dr Sanacora reported receiving personal fees and serving as a consultant to Allergan, Alkermes, AstraZeneca, Avanier Pharmaceuticals, Axsome Therapeutics, Biogen, Biohaven Pharmaceuticals, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Cowen, EMA Wellness, Engrail Therapeutics, Clexio, Denovo Biopharma, Gilgamesh, Hoffmann La-Roche, Intra-Cellular Therapies, Janssen Pharmaceuticals, Levo, Lundbeck, Merck, Navitor Pharmaceuticals, Neurocrine, Novartis, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis Therapeutics, Sage Pharmaceuticals, Servier Pharmaceuticals, Seelos Pharmaceuticals, Taisho Pharmaceuticals, Teva, Valeant, Vistagen Therapeutics, and XW Labs. Dr Sanacora also reported receiving research contracts from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, and Usona over the past 36 months. Dr. Sanacora holds equity in Biohaven Pharmaceuticals and is a co-inventor on a US patent (8,778,979) held by Yale University and a co-inventor on US Provisional Patent Application 047162-7177P1 (00754) filed on August 20, 2018, by the Yale University Office of Cooperative Research. Yale University has a financial relationship with Janssen Pharmaceuticals and may in the future receive financial benefits from this relationship. The university has put multiple measures in place to mitigate this institutional conflict of interest. Questions about the details of these measures should be directed to Yale University\u2019s Conflict of Interest office. Dr Wilkinson reported receiving contract funding from Janssen Pharmaceuticals, Sage Therapeutics, and Oui Therapeutics for the conduct of clinical trials administered through Yale University as well as consulting fees from Biohaven Pharmaceuticals, Sage Therapeutics, Janssen Pharmaceuticals, and Oui Therapeutics. No other disclosures were reported."
}